AR094214A1 - Inhibidores de la quinasa que regula la señal de la apoptosis - Google Patents
Inhibidores de la quinasa que regula la señal de la apoptosisInfo
- Publication number
- AR094214A1 AR094214A1 ARP130104949A ARP130104949A AR094214A1 AR 094214 A1 AR094214 A1 AR 094214A1 AR P130104949 A ARP130104949 A AR P130104949A AR P130104949 A ARP130104949 A AR P130104949A AR 094214 A1 AR094214 A1 AR 094214A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- diseases
- hydrogen
- cycloalkyl
- substituted
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 abstract 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 229910017711 NHRa Inorganic materials 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos presentan actividad de inhibición sobre la quinasa que regula la señal de la apoptosis (ASK1), por lo que son útiles para tratar las afecciones que están mediadas por la ASK1, lo que abarca los trastornos autoinmunes, las enfermedades inflamatorias, las enfermedades cardiovasculares, la diabetes, la nefropatía diabética, las enfermedades cardiorrenales, que abarcan las enfermedades en los riñones, las enfermedades fibróticas, las enfermedades respiratorias, la EPOC, la fibrosis pulmonar idiopática, las lesiones agudas en los pulmones, las enfermedades hepáticas agudas o crónicas y las enfermedades neurodegenerativas. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), donde R¹ es un alquilo C₁₋₃ o un cicloalquilo C₃₋₆, donde el alquilo o el cicloalquilo pueden estar sustituidos con entre uno y tres átomos halógenos; R² es hidrógeno o un alquilo C₁₋₆, donde el alquilo puede estar sustituido con un halógeno; R³ es hidrógeno o un alquilo C₁₋₃; R⁴ es hidrógeno o un alquilo C₁₋₃; R⁵ es hidrógeno, un alquilo C₁₋₃, ORᵃ o NHRᵃ; R⁶ es hidrógeno, un alquilo C₁₋₃, un haloalquilo C₁₋₃ o un cicloalquilo C₃₋₆, donde el cicloalquilo puede estar sustituido con un alquilo C₁₋₃, con un haloalquilo C₁₋₃ o con 1 ó 2 átomos halógenos; Rᵃ y Rᵇ son independientemente hidrógeno o un alquilo C₁₋₃, o Rᵃ y Rᵇ pueden combinarse con el átomo de nitrógeno al que están unidos para formar un anillo heterocíclico de seis miembros, que puede comprender un átomo de oxígeno o de nitrógeno; o una sal o un estereoisómero farmacéuticamente aceptable de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740777P | 2012-12-21 | 2012-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094214A1 true AR094214A1 (es) | 2015-07-15 |
Family
ID=49943575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104949A AR094214A1 (es) | 2012-12-21 | 2013-12-20 | Inhibidores de la quinasa que regula la señal de la apoptosis |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US9051313B2 (es) |
| EP (2) | EP3150597A1 (es) |
| JP (2) | JP6086633B2 (es) |
| KR (1) | KR101712758B1 (es) |
| CN (1) | CN104918936B (es) |
| AR (1) | AR094214A1 (es) |
| AU (2) | AU2013361140B2 (es) |
| BR (1) | BR112015014567A2 (es) |
| CA (1) | CA2896060C (es) |
| CY (1) | CY1118574T1 (es) |
| DK (1) | DK2935258T3 (es) |
| EA (1) | EA027645B1 (es) |
| ES (1) | ES2612979T3 (es) |
| HK (1) | HK1214247A1 (es) |
| HR (1) | HRP20170112T8 (es) |
| HU (1) | HUE032988T2 (es) |
| IL (2) | IL239322A (es) |
| LT (1) | LT2935258T (es) |
| MX (1) | MX2015008090A (es) |
| NZ (1) | NZ709248A (es) |
| PL (1) | PL2935258T3 (es) |
| PT (1) | PT2935258T (es) |
| RS (1) | RS55676B1 (es) |
| SG (1) | SG11201504865YA (es) |
| SI (1) | SI2935258T1 (es) |
| SM (2) | SMT201700051T1 (es) |
| TW (1) | TWI622589B (es) |
| UY (1) | UY35212A (es) |
| WO (1) | WO2014100541A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| CN102985418B (zh) * | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| UY35212A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| US9169243B2 (en) * | 2013-12-20 | 2015-10-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| US20150342943A1 (en) * | 2014-06-03 | 2015-12-03 | Gilead Sciences, Inc. | Methods of treating liver disease |
| TW201618781A (zh) * | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
| KR20190035960A (ko) | 2014-09-24 | 2019-04-03 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환의 치료 방법 |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| EP4276095A3 (en) | 2014-12-23 | 2024-01-17 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| WO2018090869A1 (zh) * | 2016-11-16 | 2018-05-24 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
| WO2018094964A1 (zh) * | 2016-11-25 | 2018-05-31 | 武汉大学 | 一种以凋亡信号调节激酶1n端二聚化为靶点筛选用于治疗脂肪性肝炎药物的方法 |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| US10787435B2 (en) | 2017-01-22 | 2020-09-29 | Fuijan Cosunter Pharmaceutical Co. Ltd. | ASK1 inhibitor and preparation method and use thereof |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法 |
| WO2018218044A2 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019046186A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
| US10370352B2 (en) | 2017-09-07 | 2019-08-06 | Eli Lilly And Company | Cyclobutyl-imidazolidinone compounds |
| WO2019047094A1 (en) * | 2017-09-07 | 2019-03-14 | Eli Lilly And Company | CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS |
| WO2019099703A1 (en) * | 2017-11-16 | 2019-05-23 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
| WO2019099203A1 (en) * | 2017-11-17 | 2019-05-23 | Hepagene Therapeutics, Inc. | Oxazole and thiazole derivatives as inhibitors of ask1 |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| CN112312905B (zh) * | 2018-05-02 | 2024-03-15 | 英安塔制药有限公司 | 含四唑的细胞凋亡信号调节激酶1抑制剂及其使用方法 |
| US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| AR115636A1 (es) * | 2018-06-27 | 2021-02-10 | Biogen Ma Inc | Agentes inhibidores de ask1 |
| CN111107848B (zh) * | 2018-08-10 | 2023-05-23 | 江苏豪森药业集团有限公司 | 一种含有酰胺类衍生物的药物组合物及其制备方法和应用 |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| ES2297424T3 (es) * | 2003-05-21 | 2008-05-01 | Boehringer Ingelheim International Gmbh | Compuestos inhibidores de la hepatitis c. |
| WO2005009470A1 (ja) | 2003-07-28 | 2005-02-03 | Osaka Industrial Promotion Organization | Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法 |
| US20070276050A1 (en) | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
| US20100144793A1 (en) | 2006-11-24 | 2010-06-10 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| KR20100075881A (ko) * | 2007-08-31 | 2010-07-05 | 메르크 세로노 에스. 에이. | 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도 |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| CN102985418B (zh) * | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| US9169243B2 (en) * | 2013-12-20 | 2015-10-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
-
2013
- 2013-12-19 UY UY0001035212A patent/UY35212A/es not_active Application Discontinuation
- 2013-12-20 JP JP2015549760A patent/JP6086633B2/ja active Active
- 2013-12-20 AR ARP130104949A patent/AR094214A1/es unknown
- 2013-12-20 BR BR112015014567A patent/BR112015014567A2/pt not_active IP Right Cessation
- 2013-12-20 LT LTEP13818940.2T patent/LT2935258T/lt unknown
- 2013-12-20 NZ NZ709248A patent/NZ709248A/en not_active IP Right Cessation
- 2013-12-20 EP EP16195735.2A patent/EP3150597A1/en not_active Withdrawn
- 2013-12-20 KR KR1020157019179A patent/KR101712758B1/ko active Active
- 2013-12-20 EP EP13818940.2A patent/EP2935258B1/en active Active
- 2013-12-20 PT PT138189402T patent/PT2935258T/pt unknown
- 2013-12-20 EA EA201591018A patent/EA027645B1/ru not_active IP Right Cessation
- 2013-12-20 SM SM20170051T patent/SMT201700051T1/it unknown
- 2013-12-20 RS RS20170126A patent/RS55676B1/sr unknown
- 2013-12-20 CN CN201380066600.1A patent/CN104918936B/zh active Active
- 2013-12-20 PL PL13818940T patent/PL2935258T3/pl unknown
- 2013-12-20 HR HRP20170112TT patent/HRP20170112T8/hr unknown
- 2013-12-20 DK DK13818940.2T patent/DK2935258T3/en active
- 2013-12-20 ES ES13818940.2T patent/ES2612979T3/es active Active
- 2013-12-20 SI SI201330489A patent/SI2935258T1/sl unknown
- 2013-12-20 WO PCT/US2013/076811 patent/WO2014100541A1/en not_active Ceased
- 2013-12-20 TW TW102147530A patent/TWI622589B/zh active
- 2013-12-20 CA CA2896060A patent/CA2896060C/en active Active
- 2013-12-20 HK HK16102017.7A patent/HK1214247A1/zh unknown
- 2013-12-20 HU HUE13818940A patent/HUE032988T2/hu unknown
- 2013-12-20 MX MX2015008090A patent/MX2015008090A/es unknown
- 2013-12-20 US US14/135,812 patent/US9051313B2/en active Active
- 2013-12-20 SG SG11201504865YA patent/SG11201504865YA/en unknown
- 2013-12-20 AU AU2013361140A patent/AU2013361140B2/en active Active
-
2015
- 2015-05-13 US US14/711,331 patent/US20150246910A1/en not_active Abandoned
- 2015-06-10 IL IL239322A patent/IL239322A/en not_active IP Right Cessation
-
2016
- 2016-09-29 JP JP2016191437A patent/JP2016222721A/ja not_active Withdrawn
- 2016-10-21 AU AU2016247182A patent/AU2016247182B2/en active Active
- 2016-11-21 US US15/357,878 patent/US9943521B2/en active Active
-
2017
- 2017-01-24 SM SM201700051T patent/SMT201700051B/it unknown
- 2017-01-31 CY CY20171100143T patent/CY1118574T1/el unknown
- 2017-11-21 IL IL255799A patent/IL255799B/en not_active IP Right Cessation
-
2018
- 2018-03-21 US US15/927,948 patent/US10307427B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094214A1 (es) | Inhibidores de la quinasa que regula la señal de la apoptosis | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR088801A1 (es) | Compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089550A1 (es) | Compuestos quimicos | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR096837A1 (es) | Heterociclos tricíclicos como inhibidores de proteínas bet | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR090867A1 (es) | Compuestos y composiciones plaguicidas y procesos relacionados | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| AR092211A1 (es) | Derivados de hidropirrolopirrol | |
| AR104762A1 (es) | Moduladores de dihidropirazol gpr40 | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR091144A1 (es) | Compuestos inhibidores de la actividad de la catecol o-metiltransferasa | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |